Treatment of early-stage Hodgkin lymphoma

Slides:

Advertisements

Similar presentations

1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 4.1 Chapter 4.

Advertisements

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes Stuart E. Samuels, MD, PhD, Matthew.

Savage KJ et al. Proc ASH 2015;Abstract 579.

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Volume 155, Issue 3, Pages (March 1996)

A Community-Based Upper-Extremity Group Exercise Program Improves Motor Function and Performance of Functional Activities in Chronic Stroke: A Randomized.

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne.

Martin Dreyling, MD, PhD Seminars in Hematology

Critical Reviews in Oncology / Hematology

Circ Cardiovasc Interv

Figure 4 Progression-free survival, according to treatment group

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Preface Surgical Oncology Clinics

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Advances in Biology, Diagnostics, and Treatment of Hodgkin’s Disease

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Obsessive Compulsive Disorder: A Clinical Update

Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine,

Volume 148, Issue 1, Pages (January 2018)

by Michael F. Leahy, and J. Harvey Turner

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 154, Issue 1, Pages (July 2013)

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Current and Future Trends in the Treatment of Renal Cancer

Ali F. AbuRahma, MD Journal of Vascular Surgery

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

George Blumenschein, MD, John V. Heymach, MD, PhD

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Volume 9, Issue 4, Pages (April 2008)

Long-term effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized controlled trial comparing two different.

D.J. Hunter Osteoarthritis and Cartilage

J Bone Miner Res 2013; doi: /jbmr.2072 (Fig. 1)

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Highlighting Unmet Needs: Real Patients, Difficult Choices

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

SYMPLICITY: not all that simple

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Marrick L. Kukin, MD Mayo Clinic Proceedings

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Treatment versus Transplant for Challenging Hematologic Disorders

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

by Andrew M. Evens, and Lale Kostakoglu

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Treatment of early-stage Hodgkin lymphoma Andreas Engert, John Raemaekers Seminars in Hematology Volume 53, Issue 3, Pages 165-170 (July 2016) DOI: 10.1053/j.seminhematol.2016.05.004 Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 1 Evolution of radiotherapy in HL. Adapted from Yahalom, Lugano, 2008. © Yahalom, J. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 2 EORTC H8F trial. Freedom from treatment failure (FFTF) for patients with early favorable HL. From Ferme et al [9]. © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 3 HD7 trial for early favorable HL (FFTF). Reprinted from Engert A et al [10]. © 2007 American Society of Clinical Oncology. All rights reserved. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 4 GHSG HD10 study. Weakest v strongest arm (FFTF). From Engert A et al [11]. © 2010 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 5 GHSG HD13 trial. Progression-free survival. Reprinted with permission from Behringer et al [12]. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 6 GHSG HD8 study. Early unfavorable HL (FFTF). Reprinted from Engert et al [13]. © 2003 American Society of Clinical Oncology. All rights reserved. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 7 GHSG HD11 trial. Early unfavorable HL (FFTF). Reprinted from Eich et al [14]. © 2010 American Society of Clinical Oncology. All rights reserved. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 8 GHSG HD14 trial. Early unfavorable HL (PFS). Reprinted from von Tresckow et al [15]. © 2012 American Society of Clinical Oncology. All rights reserved. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 9 Kaplan-Meier plots of progression-free survival. Included are data from patients with PET-negative findings who underwent randomization. The intention-to-treat analysis included 420 patients, and the per-protocol analysis included 392 patients. From Radford et al [30]. © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Seminars in Hematology 2016 53, 165-170DOI: (10.1053/j.seminhematol.2016.05.004) Copyright © 2016 Elsevier Inc. Terms and Conditions